The neuroactive steroid allopregnanolone is a potent g-aminobutyric acid type A (GABA A ) receptor modulator with anxiolytic and anticonvulsant effects. Olanzapine and clozapine also have anxiolytic-like effects in behavioral models. We therefore postulated that olanzapine and clozapine would elevate allopregnanolone levels, but risperidone and haloperidol would have minimal effects. Male rats received intraperitoneal olanzapine (2.5-10.0 mg/kg), clozapine (5.0-20.0 mg/kg), risperidone (0.1-1.0 mg/kg), haloperidol (0.1-1.0 mg/ kg), or vehicle. Cerebral cortical allopregnanolone and peripheral progesterone and corticosterone levels were determined. Adrenalectomized animals were also examined. Both olanzapine and clozapine increased cerebral cortical allopregnanolone levels, but neither risperidone nor haloperidol had significant effects. Olanzapine and clozapine also increased serum progesterone and corticosterone levels. Adrenalectomy prevented olanzapine-and clozapine-induced elevations in allopregnanolone. Allopregnanolone induction may contribute to olanzapine and clozapine anxiolytic, antidepressant, and mood-stabilizing actions. Alterations in this neuroactive steroid may result in the modulation of GABAergic and dopaminergic neurotransmission, potentially contributing to antipsychotic efficacy.
INTRODUCTION
The neuroactive steroid allopregnanolone (3a-hydroxy-5a-pregnan-20-one) is synthesized de novo in the brain from cholesterol or from peripheral steroid precursors such as progesterone, and in the adrenals and gonads (Purdy et al, 1991) . It is a positive allosteric modulator of g-aminobutyric acid type A (GABA A ) receptors, potentiating GABAergic neurotransmission in a manner that is 20-fold more potent than benzodiazepines and 200-fold more potent than barbiturates Morrow et al, 1987 Morrow et al, , 1990 . Allopregnanolone demonstrates marked anxiolytic (Crawley et al, 1986; Wieland et al, 1991) and anticonvulsant activity (Kokate et al, 1994 (Kokate et al, , 1996 Devaud et al, 1995) , likely secondary to GABA A receptor potentiation. Recent evidence also suggests that allopregnanolone may be relevant to antipsychotic drug action and schizophrenia pathophysiology (Marx et al, 2000) .
We have demonstrated previously that olanzapine increases cerebral cortical allopregnanolone levels in male rats to levels known to affect GABAergic neurotransmission (Marx et al, 2000) . Since olanzapine also demonstrates anxiolytic-like activity in animal behavioral paradigms (Arnt and Skarsfeldt, 1998) , we hypothesized that olanzapine-induced elevations in the endogenous anxiolytic neuroactive steroid allopregnanolone may contribute to these effects. In this study, we hypothesize that the antipsychotic clozapine also elevates cerebral cortical allopregnanolone levels in rats, since clozapine has anxiolytic-like effects in animals. For example, both clozapine and olanzapine increase punished responding in a conflict schedule rodent anxiety model, but risperidone and haloperidol have no significant effects (Moore et al, 1994) . We therefore hypothesize that an elevation in the anxiolytic neuroactive steroid allopregnanolone will not be present following risperidone or haloperidol administration, since these antipsychotic agents generally do not demonstrate anxiolytic effects in animal behavioral models (Arnt and Skarsfeldt, 1998; Moore et al, 1994) .
In addition to anxiolytic actions, allopregnanolone appears to have antidepressant effects (Uzunova et al, 1998; Romeo et al, 1998) . In patients with major depression receiving fluoxetine or fluvoxamine, cerebrospinal fluid allopregnanolone levels normalized with antidepressant treatment and correlated with improvement in depressive symptomatology (Uzunova et al, 1998) . Since olanzapine (Tollefson et al, 1997 (Tollefson et al, , 1998 Shelton et al, 2001 ) and clozapine (Meltzer and Okayli, 1995; Meltzer 2001 ) also appear to have antidepressant actions, it is possible that olanzapine-or clozapine-induced elevations in this neuroactive steroid may contribute to these effects. Rodent work examining fluoxetine-induced elevations in allopregnanolone demonstrates that the effect is present to the same extent in both adrenalectomized and intact animals, suggesting fluoxetine-induced de novo allopregnanolone biosynthesis in the brain (Uzunov et al, 1996) . To determine if antipsychotic-induced elevations in cerebral cortical allopregnanolone are similarly independent of adrenal progesterone or allopregnanolone production, adrenalectomized animals were examined to clarify the mechanism of this neuroactive steroid alteration.
An extensive literature documents the anticonvulsant effects of allopregnanolone utilizing a number of animal seizure models (Kokate et al, 1994 (Kokate et al, , 1996 Belelli et al, 1989; Gasior et al, 1997; Devaud et al, 1995) . Since anticonvulsants are frequently used in the pharmacological treatment of psychiatric illnesses such as bipolar disorder, and since both olanzapine (Tohen et al, 1999 and clozapine (Suppes et al, 1999; Green et al, 2000) are effective antimanic agents, antipsychotic-induced elevations in this neuroactive steroid may contribute to this clinical effect. In summary, the GABAergic neuroactive steroid allopregnanolone has anxiolytic, antidepressant, and anticonvulsant effects, and the atypical antipsychotics olanzapine and clozapine demonstrate anti-anxiety, antidepressant, and antimanic actions. Allopregnanolone induction could therefore be relevant to these therapeutic actions.
In the following experiments, we determined the specificity of antipsychotic-induced alterations in the GABAergic neurosteroid allopregnanolone by administering olanzapine, clozapine, risperidone, or haloperidol intraperitoneally at pharmacologically relevant doses to male rats. We also investigated serum progesterone and corticosterone levels following antipsychotic treatment to determine the specificity of these steroid alterations in rodents, and to determine if peripheral serum progesterone levels are correlated with cerebral cortical allopregnanolone levels.
METHODS
All experiments were conducted in accordance with National Institutes of Health Guidelines under Institution Animal Care and Use Committee-approved protocols. Male Sprague-Dawley rats (200-250 mg) were purchased from Harlan (Indianapolis, IN). Rats were housed three per cage and placed on a 12-h light-dark cycle (lights on, 6:00 am to 6:00 pm) with ad libitum access to rat chow and water. All rats were handled and habituated to intraperitoneal (i.p.) vehicle injection (0.9% saline) for 5 days prior to the day of the experiment to minimize possible stress-induced steroid increases. All experiments were performed at the beginning of the light cycle between 9:00 am and noon to minimize diurnal steroid fluctuations.
Antipsychotic Administration and Dosing
Olanzapine (Eli Lilly and Company, Indianapolis, IN) , was dissolved in a small amount of 20% acetic acid (0.5 ml or less) and then diluted with 0.9% saline (final acetic acid concentration 0.2%). Clozapine (Sigma, St Louis, MO) was prepared in a similar manner. Risperidone (Sigma, St Louis, MO) was dissolved in 45% w/v 2-hydroxypropyl-b-cyclodextrin (Sigma, St Louis, MO) and then diluted with distilled water (final 2-hydroxypropyl-b-cyclodextrin concentration 22.5%). Haloperidol 2.0 mg/ml liquid (Pai Pharmaceutical Associates Inc., Greenville, SC) was diluted with 0.9% saline. The vehicle consisted of 0.2% acetic acid in 0.9% saline.
On the day of the experiment, antipsychotics were administered i.p. at the following doses: olanzapine 0, 2.5, 5.0, or 10.0 mg/kg, clozapine 0, 5.0, 10.0, or 20.0 mg/kg, risperidone 0, 0.1, 0.5, or 1.0 mg/kg, and haloperidol 0, 0.1, 0.5, or 1.0 mg/kg, n ¼ 6-11 animals per treatment condition. Dose-response experiments were repeated two additional times for each antipsychotic. Results were consistently replicated, and therefore the three dose-response experiments for each antipsychotic were combined, final n ¼ 17-31 per treatment condition.
In designing these experiments, we targeted rodent dosing strategies relevant to antipsychotic dosing in human subjects (Mukherjee et al, 2001; Kapur et al, 1998 Kapur et al, , 1999 and consistent with doses utilized in the existing rodent literature Kinkead et al, 2000; Atkins et al, 1999; Zhang et al, 2000) . Therapeutic response is frequently associated with D 2 receptor occupancy of approximately 60-70% in humans, but D 2 occupancies greater than 80% are associated with increased extrapyramidal side effects. Both haloperidol and risperidone 0.1 mg/kg doses produce striatal D 2 receptor occupancies that exceed 80% in rodents (Mukherjee et al, 2001 ). In addition, the reported ED 50 values for risperidone to block behavioral effects of dopamine agonists are between 0.06 and 0.1 mg/kg (Janssen et al, 1988; Megens et al, 1994; Arnt, 1995) . Similarly, olanzapine (Bymaster et al, 1996) and clozapine (Mukherjee et al, 2001 ) dose ranges in this study are known to produce rodent D 2 receptor occupancies comparable to D 2 occupancies demonstrated in humans receiving these compounds (Kapur et al, 1998 (Kapur et al, , 1999 .
Olanzapine, clozapine, and risperidone are also potent 5HT 2 antagonists in the dose ranges utilized in this study (Bymaster et al, 1996) , corresponding to the extent of 5HT 2 blockade observed in human subjects (Kapur et al, 1998 (Kapur et al, , 1999 . For blocking 5HT 2A -mediated responses in vivo, ED 50 values for risperidone are 0.02-0.03 mg/kg (Janssen et al, 1988; Megens et al, 1994; Zhang and Bymaster, 1999) . The highest risperidone dose of 1.0 mg/kg utilized in this study is, therefore, a high dose of this drug with regard to D 2 and 5HT 2 antagonism, two pharmacological properties likely relevant to therapeutic response. Finally, the antipsychotic dose ranges utilized in these experiments are also consistent with prior dosing strategies to investigate anxiolytic-like effects in rodent behavioral models (Moore et al, 1992; Wiley et al, 1993; Inoue et al, 1996) . Rodent investigations examining clozapine anxiolytic-like effects utilized maximal clozapine doses of 5.0-10.0 mg/kg (Spealman and Katz, 1980; Moore et al, 1994; Inoue et al, 1996) .
To ensure an adequate dose range for this antipsychotic, we also included a 20.0 mg/kg clozapine dose.
Tissue Procurement
Rats were killed by decapitation 1 h following i.p. antipsychotic administration. The cerebral cortex was rapidly dissected on ice and stored at À801C until radioimmunoassay (RIA) determination. Trunk blood was collected for serum progesterone and corticosterone determination and stored on ice until centrifugation for serum collection.
Radioimmunoassays
Allopregnanolone levels were measured in the cerebral cortex as described previously (Janis et al, 1998; VanDoren et al, 2000) with a modification of the methods of Purdy et al (1990) . Allopregnanolone was extracted from individual cerebral cortical hemispheres prior to RIA determination. Recovery was monitored by the incorporation of 4000 dpm of [ This antiserum has minimal crossreactivity with other circulating steroids (Finn and Gee, 1994; Janis et al, 1998) . Crossreactivity with allopregnanolone 3b stereoisomers (3b-hydroxy-5a-pregnan-20-one and 3b-hydroxy-5b-pregnan-20-one) is minimal (2.8 and 0.5%, respectively). Crossreactivity with the allopregnanolone 5b stereoisomer (3a-hydroxy-5b-pregnan-20-one) is 6.6%. Although this 5b stereoisomer is present in humans, it is present in very low concentrations or undetectable in rats. Sample values were compared to a concurrently run allopregnanolone standard curve produced using a one-site competition model (Prism2; GraphPad, San Diego, CA). Sample values were adjusted to account for the previously determined extraction efficiency. The sensitivity of the assay was 20 pg/tube. Serum progesterone and corticosterone were assayed in duplicate with commercially available RIA kits utilizing 125 Iprogesterone and 125 I-corticosterone (ICN Pharmaceuticals, Costa Mesa, CA) according to the manufacturer's instructions. The limits of detection for the progesterone and corticosterone assays were 0.1 and 10 ng/ml, respectively. Serum progesterone levels were diluted prior to progesterone determination to achieve values within the standard curve of the commercial kit.
Adrenalectomy Experiments
Male adrenalectomized and sham-operated rats were purchased from Harlan (Indianapolis, IN). Experiments were performed 5-6 days following surgery (and 1-2 days following arrival to the animal colony at our institution). Adrenalectomized animals received 0.9% saline instead of water ad libitum. Sham-operated animals received water ad libitum. All animals had free access to rat chow. On the day of the experiment, adrenalectomized animals were injected i.p. with olanzapine 10.0 mg/kg (prepared as described previously) or vehicle (0.2% acetic acid in 0.9% saline), and sham-operated animals were injected i.p. with either olanzapine 10.0 mg/kg or vehicle, n ¼ 9-11 animals per condition. The same experiment was performed utilizing clozapine 20.0 mg/kg as the antipsychotic of interest instead of olanzapine. Rats were decapitated 1 h following i.p. antipsychotic or vehicle injection, and cerebral cortex and trunk blood were collected as described above.
Statistics
Statistical analysis of dose-response antipsychotic experiment results was conducted by ANOVA, including post hoc Dunnett tests. Linear regression analysis was used to determine Pearson's correlation coefficients. Analysis of the adrenalectomy experiments was conducted utilizing two-tailed t-tests. All data are expressed as the mean 7 standard error of the mean (SEM).
RESULTS

Olanzapine-and Clozapine-Induced Alterations in Cerebral Cortical Allopregnanolone
Cerebral cortical allopregnanolone levels were markedly increased 60 min following i.p. olanzapine (2.5-10.0 mg/kg) and i.p. clozapine (5.0-20.0 mg/kg) administration in male Sprague-Dawley rats (Figures 1a and 2a) . Elevations in allopregnanolone were most pronounced following olanzapine treatment. Changes in cerebral cortical allopregnanolone levels induced by olanzapine and clozapine were dose-dependent and specific to these two antipsychotics. 
Antipsychotic-Induced Alterations in Serum Progesterone Precursor
Serum progesterone precursor was dramatically increased 60 min following olanzapine and clozapine i.p. administration up to 58-and 47-fold, respectively (Figures 1b and 2b ) . Serum progesterone alterations induced by olanzapine and clozapine were dose-dependent and highly significant. Olanzapine treatment had the most pronounced effects on serum progesterone in male rats. Olanzapine 5.0 mg/kg (n ¼ 21) and 10.0 mg/kg (n ¼ 31) elevated serum progesterone levels to 42.83 7 11.15 and 97.00 7 10.69 ng/ml, respectively, compared to vehicle levels (n ¼ 30) of 1.684 7 0.162 ng/ml ( Figure Risperidone also had significant effects on serum progesterone levels, but elevations were less robust than olanzapine-or clozapine-induced alterations in this steroid ( Figure 3c ) Risperidone 1.0 mg/kg (n ¼ 20) elevated serum progesterone 20-fold to 41.29 7 16.45 ng/ml compared to vehicle levels (n ¼ 27) of 2.070 7 0.203 ng/ml (Figure 3c) (ANOVA: p ¼ 0.0019; F ¼ 5.453; df ¼ 3,79; n ¼ 18-27 animals per condition; post hoc Dunnett tests: **po0.01 for risperidone 1.0 mg/kg condition). In contrast, haloperidol had very modest effects on serum progesterone levels compared to olanzapine-, clozapine-, and risperidoneinduced alterations (Figure 3d ). Haloperidol 1.0 mg/kg (n ¼ 20) elevated serum progesterone levels 2.7-fold to 5.533 7 2.072 ng/ml compared to vehicle levels (n ¼ 27) of 2.060 7 0.205 ng/ml (ANOVA: p ¼ 0.0463; F ¼ 2.784l; df ¼ 3,78; n ¼ 17-27 animals per condition; post hoc Dunnett tests: *po0.05 for haloperidol 1.0 mg/kg condition). 
Antipsychotic-Induced Alterations in Serum Corticosterone
Olanzapine and clozapine demonstrated pronounced dosedependent effects on serum corticosterone 60 min following i.p. injection in male Sprague-Dawley rats, increasing corticosterone up to 10-and 8.5-fold, respectively (Table 1) . Olanzapine 5.0 mg/kg (n ¼ 21) and 10.0 mg/kg (n ¼ 31) increased serum corticosterone levels to 445.9 7 57.0 and 824.8 7 82.6 ng/ml, respectively, compared to vehicle levels (n ¼ (Table 1) . Risperidone also had significant effects on serum corticosterone, but effects were less pronounced compared to olanzapine-and clozapine-induced alterations in this steroid. Risperidone 1.0 mg/kg (n ¼ 20) increased serum corticosterone levels to 438.5 7 85.73 ng/ml compared to vehicle levels (n ¼ 28) of 118.4 7 32.2 ng/ml, a 3.7-fold increase (ANOVA: po0.0001, F ¼ 10.83, df ¼ 3,81; n ¼ 18-28 animals per condition; post hoc Dunnett test: **po0.01 for risperidone 1.0 mg/kg condition) ( Table 1) . Haloperidol 1.0 mg/kg (n ¼ 20) had more modest effects on corticosterone, increasing serum corticosterone levels 2.4-fold up to 284.6 7 74.7 ng/ml compared to vehicle levels (n ¼ 28) of 120.7 7 34.1 ng/ml (ANOVA: p ¼ 0.0211; F ¼ 3.421; df ¼ 3,81; n ¼ 18-28 animals per condition; post hoc Dunnett tests: *po0.05 for haloperidol 1.0 mg/kg condition) ( Table 1) .
Adrenalectomy Prevents Olanzapine-and Clozapine-Induced Elevations in Cerebral Cortical Allopregnanolone
Olanzapine 10.0 mg/kg increases cerebral cortical allopregnanolone in sham-operated animals (n ¼ 11) to 2.536 7 0.293 ng/g compared to levels in vehicle-treated sham-operated animals (n ¼ 9) of 0.738 7 0.1183 ng/g (twotailed t-test: ***po0.0001; t ¼ 6.111; df ¼ 18) (Figure 4a ). In contrast, adrenalectomy prevents olanzapine-induced increases in cerebral cortical allopregnanolone levels ( Figure 4b ). Allopregnanolone levels in adrenalectomized animals treated with olanzapine 10.0 mg/kg were very similar to adrenalectomized animals treated with vehicle, 0.403 7 0.055 vs 0.477 7 0.089 ng/g, respectively (two-tailed t-test: p ¼ 0.3109; t ¼ 1.043; df ¼ 18; n ¼ 10 animals per condition) (Figure 4b ).
Very similar results were obtained utilizing clozapine in this experimental paradigm. Clozapine 20.0 mg/kg increases cerebral cortical allopregnanolone in sham-operated animals (n ¼ 9) to 1.543 7 0.217 ng/g compared to levels in vehicle-treated sham-operated animals (n ¼ 10) of 0.089 7 0.037 ng/g (two-tailed t-test ***po0.0001; t ¼ 6.964; df ¼ 17) (Figure 5a ). Adrenalectomy prevents clozapine-induced increases in cerebral cortical allopregnanolone levels (Figure 5b ). Allopregnanolone levels in adrenalectomized animals treated with clozapine 20.0 mg/ kg were very similar to adrenalectomized animals treated with vehicle, 0.125 7 0.076 vs 0.046 7 0.006 ng/g (two-tailed t-test: p ¼ 0.3109; t ¼ 1.043; df ¼ 18, n ¼ 10 animals per condition) (Figure 5b ).
DISCUSSION
Olanzapine and Clozapine Effects on Cerebral Cortical Allopregnanolone
We have demonstrated that acute olanzapine and clozapine administration dose-dependently and specifically increases the GABAergic neuroactive steroid allopregnanolone in rat cerebral cortex to concentrations known to potentiate GABA A receptor function (3.0-4.0 ng/g or 10-13 nM) Morrow et al, 1987 Morrow et al, , 1990 . Allopregnanolone levels in the cerebral cortex following clozapine administration in these experiments are comparable to levels reported recently by Barbaccia et al (2001) , utilizing 10.0 and 20.0 mg/kg dosing strategies. In contrast to olanzapine and clozapine, the antipsychotics risperidone and haloperidol had no significant effects on allopregnanolone levels in the cerebral cortex, confirming our initial hypothesis. We had predicted that both olanzapine and clozapine would increase the anxiolytic neuroactive steroid allopregnanolone, since these antipsychotics produce marked anxiolytic-like effects in rodent behavioral models. Since risperidone and haloperidol have minimal anxiolytic-like effects in these behavioral paradigms, we predicted that these antipsychotics would not alter rodent cortical allopregnanolone levels. It is therefore possible that olanzapine-and clozapine-induced elevations in the anxiolytic neuroactive steroid allopregnanolone contribute to the anxiolytic-like effects of these compounds. The absence of haloperidol-induced effects on this neuroactive steroid is consistent with recent efforts by Barbaccia et al (2001) . To our knowledge, this is the first report demonstrating that acute risperidone administration does not affect central allopregnanolone levels. We have not excluded the possibility that risperidone dosing greater than 1.0 mg/kg may be required to produce significant elevations in cerebral cortical allopregnanolone. Exceeding 1.0 mg/kg risperidone dosing in rodents would likely have limited clinical relevance, however, since 1.0 mg/ kg dosing of this compound produces D 2 receptor occupancy greater than 90% (Mukherjee et al, 2001 ) and considerable sedation. In humans, striatal D 2 occupancy greater than 80% is associated with extrapyramidal side effects (Farde et al, 1992) . This 90% D 2 occupancy rate following rodent 1.0 mg/kg dosing also exceeds D 2 occupancy rates observed in human subjects receiving clinically therapeutic doses of risperidone. For example, patients with schizophrenia receiving 2.0-6.0 mg/day of risperidone demonstrate D 2 occupancy rates of 63-85% (Kapur et al, 1999) . It is therefore unlikely that risperidone dosing greater than 1.0 mg/kg in rodents would yield clinically useful information.
These data suggest that olanzapine and clozapine may alter GABAergic neurotransmission by allopregnanolone induction, a possibility that may be relevant to the therapeutic actions of these compounds in patients with schizophrenia. Numerous studies examining postmortem tissue from subjects with schizophrenia suggest that GABAergic neurotransmission may be altered in the disorder, and that a deficiency in the GABA neurotransmitter system may be present (Benes and Berretta, 2001; Akbarian et al, 1995; Lewis, 2000) . In addition, GABA A receptor agonists such as benzodiazepines are helpful in the treatment of schizophrenia in certain circumstances (Carpenter et al, 1999) . Olanzapine-and clozapine-induced elevations in the GABAergic neuroactive steroid allopregnanolone may, therefore, represent a mechanism by which these compounds alter GABAergic neurotransmission in schizophrenia, possibly modulating this pathophysiologic component of the disorder and contributing to antipsychotic efficacy. The investigation of rodents treated with olanzapine and clozapine chronically will be necessary to determine if olanzapine-and clozapine-induced elevations in this neuroactive steroid persist with prolonged treatment and contribute to the long-term benefits of these antipsychotics.
Evidence suggests that allopregnanolone may also modulate dopaminergic neurotransmission. Specifically, allopregnanolone decreases stress-induced dopamine release in rodent cerebral cortex and nucleus accumbens (Motzo et al, 1996) and influences dopamine-mediated rodent behaviors (Khisti et al, 2002) . The GABAergic neuroactive steroid 3a,21-dihydroxy-5a-pregnan-20-one (THDOC) also decreases stress-induced prefrontal cortical dopamine release (Grobin et al, 1992) . Interestingly, recent evidence suggests that THDOC is also altered in subjects with depression; this neuroactive steroid appears to be increased during depression and decreased following antidepressant treatment, in contrast to allopregnanolone (Ströhle et al, 1999 (Ströhle et al, , 2000 . Intraventricular allopregnanolone induces catalepsy in mice (Khisti et al, 1998) , and this effect is reversed by GABAergic antagonists and dopaminergic agonists, and potentiated by the dopaminergic antagonist haloperidol. Allopregnanolone does not demonstrate activity at dopamine receptors, and therefore these effects on dopaminergic neurotransmission may be mediated by GABA A receptors. Allopregnanolone interactions with the dopamine neurotransmitter system may be important, since the dopamine hypothesis of schizophrenia has proved to be an enduring theoretical construct (Weinberger et al, 1988; Davis et al, 1991; Goldstein and Deutch, 1992) , and recent imaging efforts have provided direct evidence that dopamine is altered in the disorder Abi-Dargham et al, 1998 , 2000 .
In our experiments, adrenalectomy prevented olanzapineand clozapine-induced elevations in cerebral cortical allopregnanolone, suggesting that these effects are dependent on progesterone or allopregnanolone formation in the adrenal glands. Other recent efforts have also demonstrated that adrenalectomy prevents clozapine-induced cerebral cortical allopregnanolone formation (Barbaccia et al, 2001) . We report for the first time that adrenalectomy also prevents olanzapine-induced elevations in this neuroactive steroid. Progesterone and allopregnanolone are lipophilic compounds, and several investigations have demonstrated that progesterone crosses the blood-brain barrier easily from the periphery into the central nervous system (Raisingham et al, 1968; Pepe and Rothchild, 1973; Karavolas et al, 1979) . It is therefore possible that serum progesterone rapidly crosses the blood brain-barrier into the cerebral cortex prior to metabolism to allopregnanolone in the brain following acute treatment with olanzapine or clozapine. Our findings that serum progesterone levels are correlated with cerebral cortical allopregnanolone levels following olanzapine (r ¼ 0.7649) and clozapine (r ¼ 0.5583) administration support this possibility. Allopregnanolone production in the adrenal glands may also contribute to cerebral cortical allopregnanolone elevations, since this neuroactive steroid also crosses the blood-brain barrier readily.
The precise mechanisms leading to increased adrenal progesterone formation following treatment with olanzapine and clozapine are currently unclear. It is possible that olanzapine and clozapine act directly on adrenal enzymes leading to progesterone synthesis and significantly increase adrenal progesterone production in this manner. Alternatively, increased adrenal progesterone secretion may result from hypothalamic-pituitary-adrenal (HPA) axis activation. These possibilities will require further investigation.
In contrast, fluoxetine administration dose-dependently increases brain allopregnanolone levels in both adrenalectomized and intact rats, and therefore the absence of adrenal progesterone or allopregnanolone formation does not prevent or reduce this effect (Uzunov et al, 1996) . Evidence indicates that fluoxetine increases allopregnanolone by acting directly on the 3a-hydroxysteroid dehydrogenase (3a-HSD) enzyme and maximizing its efficiency, resulting in enhanced allopregnanolone formation from its immediate precursor 5a-dihydroprogesterone ( Griffin and Mellon, 1999) . It is not known currently if olanzapine or clozapine have similar effects on 3a-HSD activity or if other mechanisms may be responsible for allopregnanolone induction following the administration of these antipsychotics. Further research examining olanzapine and clozapine effects on 3a-HSD kinetics and 5a-reductase activity will be required to explore the possibility of potential antipsychotic effects on the enzymes leading to allopregnanolone biosynthesis.
Olanzapine and Clozapine Effects on Serum Progesterone
Both olanzapine and clozapine produced marked dosedependent increases in serum progesterone up to 58-and 47-fold, respectively, in male rats. Risperidone had less marked effects (20-fold increases compared to vehicle at the highest dose tested) and haloperidol had minimal effects (2.7-fold increases compared to vehicle at the highest dose tested) on progesterone levels. While progesterone has been viewed most frequently in the context of ovarian secretion, adrenal synthesis appears to be functionally significant in rodents (Feder and Ruf, 1969; Walker et al, 2001 ) and may be relevant to nonreproductive functions in both males and females. For example, recent evidence suggests that progesterone actions contribute to central nervous system integrity. Progesterone has been reported to increase the number of oligodendrocytes expressing myelin basic protein (Jung-Testas et al, 1992, 1999) , signal the initiation and enhance the rate of myelin formation (Chan et al, 1998) , and increase remyelination following sciatic nerve injury (Koenig et al, 1995; Baulieu and Schumacher, 2000) . Consequently, olanzapine-or clozapine-induced elevations in this steroid may be relevant to the regulation of myelination in the central nervous system. Interestingly, evidence from DNA microarray efforts examining gene expression levels in postmortem dorsolateral prefrontal cortex suggests an alteration in the expression of myelination-related genes in schizophrenia and potential disruption in oligodendrocyte function (Hakak et al, 2001) . Neuroimaging approaches also suggest that white matter integrity is altered in schizophrenia (Lim et al, 1998 (Lim et al, , 1999 Sigmundsson et al, 2001) . Olanzapine-or clozapineinduced elevations in serum progesterone, a molecule with the capacity to cross the blood-brain barrier rapidly and influence oligodendrocyte myelination, may therefore play a role in modulating myelin formation in schizophrenia. Recent imaging evidence suggesting that olanzapine treatment in first-episode psychosis patients increases white matter volume supports the possibility that olanzapine-mediated progesterone induction may be important in the pathophysiology and treatment of the disorder.
Olanzapine and Clozapine Effects on Serum Corticosterone
Olanzapine and clozapine also induced marked corticosterone elevations up to 10-and 8.5-fold, respectively. Risperidone significantly increased corticosterone (3.7-fold compared to vehicle at the highest dose tested), but less markedly than olanzapine or clozapine. Haloperidol had more modest effects on corticosterone levels (2.4-fold increases compared to vehicle at the highest dose tested). The neurochemical mechanism responsible for this effect on the HPA axis is unclear and its potential clinical significance is currently unknown. The HPA axis appears to be altered in patients with schizophrenia , but the clinical literature is not conclusive (Marx and Lieberman, 1998) . Schizophrenia is frequently characterized as a stress-sensitive illness, however, and stressful life events are associated with symptom exacerbation risk. It is therefore possible that antipsychotic-induced HPA axis alterations may be relevant to stress modulation in schizophrenia and antipsychotic treatment response. Accompanying elevations in cerebral cortical allopregnanolone may function to modulate this corticosterone response and ultimately suppress the HPA axis , since allopregnanolone inhibits corticosterone release in rodents (Patchev et al, 1996; Guo et al, 1995) .
Although corticosterone elevations are present following acute antipsychotic administration in rodents, it is uncertain if these effects persist with chronic treatment. In patients with schizophrenia treated with clozapine, cortisol levels were not elevated following treatment for 6 weeks compared to baseline , suggesting that these effects may not be present following chronic antipsychotic exposure. It is possible that clozapine-or olanzapine-induced cerebral cortical allopregnanolone may play a role in modulating acute corticosterone elevations and ensure the eventual return to lower levels of this steroid with prolonged antipsychotic treatment. Evidence that allopregnanolone decreases corticotropin-releasing factor (CRF) and adrenocorticotropin hormone (ACTH) in rodents supports this possibility (Patchev et al, 1994 (Patchev et al, , 1996 .
RODENT DATA COMPARED TO HUMAN STUDIES
HPA axis activation in rodents resulting in marked corticosterone and progesterone release is well-characterized, but very little information is available regarding stressinduced progesterone alterations in human male subjects. Similar to the rodent literature, however, stress appears to induce both progesterone and cortisol release in humans. For example, physical stress combined with sleep and calorie deprivation in males undergoing military endurance training results in significant progesterone and cortisol plasma elevations (Opstad, 1992) . In addition, several studies have demonstrated that 2-deoxyglucose (2-DG) administration resulting in a clinical state similar to hypoglycemia also produces significant progesterone and cortisol elevations in healthy male subjects (Elman and Breier, 1997) . Compared to the rodent stress response, these elevations are less pronounced, however, consisting of 2 to 3-fold increases in progesterone and cortisol following this particular metabolic stressor. 2-DG-induced elevations in progesterone and cortisol have also been observed in male control subjects and patients with schizophrenia (Breier and Buchanan, 1992) , and in healthy male subjects and abstinent alcoholic patients (George et al, 1994) . Interestingly, patients with schizophrenia (drug-free 8-77 days, n ¼ 9) achieved significantly higher serum progesterone levels than control subjects following 2-DG administration, and tended to have higher baseline progesterone levels as well (Breier and Buchanan, 1992) . Potential antipsychotic effects on peripheral progesterone levels in male patients with schizophrenia are currently unknown and will require further investigation.
Although the precise function and regulation of progesterone produced in the human adrenal have not been completely characterized, this neuroactive steroid may play an important role in the stress response and serve as a precursor to adrenal GABAergic neurosteroids such as allopregnanolone. For example, CRF challenge elevates both serum progesterone and allopregnanolone levels in human subjects (Genazzani et al, 1998) . Interestingly, progesterone elevations in this study preceded allopregnanolone elevations by approximately 30 min, suggesting that CRF challenge may result in progesterone metabolism to allopregnanolone in the adrenal. This sequence of events may be highly relevant to the regulation of the stress response, since rodent data suggest that allopregnanolone negatively modulates the HPA axis (Guo et al, 1995; Patchev et al, 1994 Patchev et al, , 1996 . Recent evidence in human subjects demonstrating that allopregnanolone and cortisol levels are inversely related both at baseline and following mental stress also supports this possibility (Girdler et al, 2001 ).
It will also be important to determine if adrenal progesterone formation in humans is relevant to the regulation of allopregnanolone in the brain, potentially providing precursor for allopregnanolone biosynthesis in the central nervous system. Since many neuroactive steroids such as progesterone formed in the periphery cross the blood-brain barrier easily, the relative contribution of peripheral steroids to central neuroactive steroid formation in humans has been very difficult to determine. At this time, the dynamics of neurosteroid biosynthesis are largely unknown and this important research area will require future investigation.
POTENTIAL CLINICAL RAMIFICATIONS OF OLANZAPINE-AND CLOZAPINE-INDUCED NEUROACTIVE STEROID ALTERATIONS
Although clinical studies examining allopregnanolone in human subjects are currently limited in number, alterations in this neuroactive steroid in cerebrospinal fluid have been associated with improvement in depressive symptomatology (Uzunova et al, 1998) . These findings may be relevant to schizophrenia, since depressive symptomatology frequently accompanies the illness (Keck et al, 2000) . Interestingly, olanzapine appears to have antidepressant effects in patients with schizophrenia (Tollefson et al, 1997 (Tollefson et al, , 1998 and resistant major depression (Shelton et al, 2001) . Clozapine also appears to have antidepressant effects, reducing suicidality, depression, and hopelessness in patients with schizophrenia (Meltzer and Okayli, 1995; Meltzer, 2001) , and may be helpful in the treatment of psychotic depression (Ranjan and Meltzer, 1995) . Given this clinical evidence suggesting that olanzapine and clozapine have antidepressant effects and data demonstrating the correlation of allopregnanolone levels with the alleviation of depressive symptoms (Uzunova et al, 1998) , we suggest that olanzapine-and clozapine-induced increases in cerebral cortical allopregnanolone may contribute to the antidepressant effects of these two compounds.
In addition to these antidepressant actions, both olanzapine and clozapine appear to have antimanic and moodstabilizing properties in the treatment of bipolar disorder. Olanzapine recently received Federal Drug Administration approval for the treatment of acute manic episodes associated with bipolar disorder based on data from two placebo-controlled clinical trials (Tohen et al, 1999; McElroy et al, 1998) , and may be effective in long-term treatment (Sanger et al, 2001) . Clozapine also appears to have independent mood-stabilizing properties (Green et al, 2000; Suppes et al, 1999; Zarate et al, 1995) . It is known that allopregnanolone has anticonvulsant effects in a number of seizure models, and anticonvulsants such as carbamazepine, valproic acid, and lamotrigine have demonstrated efficacy in the treatment of bipolar disorder. It is therefore possible that olanzapine-and clozapine-induced elevations in cerebral cortical allopregnanolone contribute to the antimanic and mood-stabilizing effects associated with these antipsychotics. Recent evidence that the anticonvulsant carbamazepine elevates cerebral cortical allopregnanolone supports the possibility that this neuroactive steroid may be relevant to mood stabilization in the treatment of bipolar disorder (Serra et al, 2000) .
Allopregnanolone induction following antipsychotic administration may also be relevant to gender differences in schizophrenia illness course and treatment response. Specifically, most clinical studies indicate that females with schizophrenia have a more favorable response to antipsychotic treatment and lower relapse rates (Seeman, 1986 , Angermeyer et al, 1990 Szymanski et al, 1995) . The mechanisms responsible for these effects are not clear, but it has been suggested that higher serum drug levels in females receiving antipsychotics may contribute to these sex differences (Seeman, 1997) . Higher drug levels in female patients with schizophrenia have been observed following fluphenazine decanoate (Simpson et al, 1990) , clozapine (Szymanski et al, 1996) , and olanzapine treatment (Kelly et al, 1999) . Since olanzapine-and clozapine-induced allopregnanolone elevations appear to be dose-dependent, potential increases in this neuroactive steroid in females may be more pronounced in the setting of higher serum antipsychotic levels compared to males. In addition, allopregnanolone and its precursor progesterone are present in higher quantities in females compared to males (Paul and Purdy, 1992) and vary across the menstrual cycle (Genazzani et al, 1998) . Olanzapine-and clozapine-induced allopregnanolone elevations may therefore be greater in females following antipsychotic treatment, secondary to higher baseline levels of these steroids in females and potential dose-related effects. Should allopregnanolone induction prove to be relevant to olanzapine or clozapine efficacy, higher allopregnanolone levels in females may contribute to the etiology of gender differences in antipsychotic treatment response.
OVERVIEW
In summary, olanzapine and clozapine have marked effects on cerebral cortical allopregnanolone, serum progesterone precursor, and serum corticosterone in these experiments. If the steroid milieu in the brain is also altered in humans following antipsychotic administration, pharmacologic treatment may result in neuroactive hormone effects in the central nervous system. Possible neurosteroid actions include the modulation of cerebral cortical GABAergic and dopaminergic neurotransmission, myelination processes, HPA axis activity, and gender-related treatment response.
